Literature DB >> 20660365

GLI2-mediated melanoma invasion and metastasis.

Vasileia-Ismini Alexaki1, Delphine Javelaud, Leon C L Van Kempen, Khalid S Mohammad, Sylviane Dennler, Flavie Luciani, Keith S Hoek, Patricia Juàrez, James S Goydos, Pierrick J Fournier, Claire Sibon, Corine Bertolotto, Franck Verrecchia, Simon Saule, Veronique Delmas, Robert Ballotti, Lionel Larue, Philippe Saiag, Theresa A Guise, Alain Mauviel.   

Abstract

BACKGROUND: The transforming growth factor-beta (TGF-beta) pathway, which has both tumor suppressor and pro-oncogenic activities, is often constitutively active in melanoma and is a marker of poor prognosis. Recently, we identified GLI2, a mediator of the hedgehog pathway, as a transcriptional target of TGF-beta signaling.
METHODS: We used real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blotting to determine GLI2 expression in human melanoma cell lines and subsequently classified them as GLI2high or as GLI2low according to their relative GLI2 mRNA and protein expression levels. GLI2 expression was reduced in a GLI2high cell line with lentiviral expression of short hairpin RNA targeting GLI2. We assessed the role of GLI2 in melanoma cell invasiveness in Matrigel assays. We measured secretion of matrix metalloproteinase (MMP)-2 and MMP-9 by gelatin zymography and expression of E-cadherin by western blotting and RT-PCR. The role of GLI2 in development of bone metastases was determined following intracardiac injection of melanoma cells in immunocompromised mice (n = 5-13). Human melanoma samples (n = 79) at various stages of disease progression were analyzed for GLI2 and E-cadherin expression by immunohistochemistry, in situ hybridization, or RT-PCR. All statistical tests were two-sided.
RESULTS: Among melanoma cell lines, increased GLI2 expression was associated with loss of E-cadherin expression and with increased capacity to invade Matrigel and to form bone metastases in mice (mean osteolytic tumor area: GLI2high vs GLI2low, 2.81 vs 0.93 mm(2), difference = 1.88 mm(2), 95% confidence interval [CI] = 1.16 to 2.60, P < .001). Reduction of GLI2 expression in melanoma cells that had expressed high levels of GLI2 substantially inhibited both basal and TGF-beta-induced cell migration, invasion (mean number of Matrigel invading cells: shGLI2 vs shCtrl (control), 52.6 vs 100, difference = 47.4, 95% CI = 37.0 to 57.8, P = .024; for shGLI2 + TGF-beta vs shCtrl + TGF-beta, 31.0 vs 161.9, difference = -130.9, 95% CI = -96.2 to -165.5, P = .002), and MMP secretion in vitro and the development of experimental bone metastases in mice. Within human melanoma lesions, GLI2 expression was heterogeneous, associated with tumor regions in which E-cadherin was lost and increased in the most aggressive tumors.
CONCLUSION: GLI2 was directly involved in driving melanoma invasion and metastasis in this preclinical study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660365      PMCID: PMC2914763          DOI: 10.1093/jnci/djq257

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  49 in total

Review 1.  Hedgehog signaling in animal development: paradigms and principles.

Authors:  P W Ingham; A P McMahon
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

Review 2.  Focus on melanoma.

Authors:  Alan N Houghton; David Polsky
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

Review 3.  Developmental roles and clinical significance of hedgehog signaling.

Authors:  Andrew P McMahon; Philip W Ingham; Clifford J Tabin
Journal:  Curr Top Dev Biol       Date:  2003       Impact factor: 4.897

Review 4.  Role of cadherins and matrixins in melanoma.

Authors:  C Gruss; M Herlyn
Journal:  Curr Opin Oncol       Date:  2001-03       Impact factor: 3.645

Review 5.  Gli and hedgehog in cancer: tumours, embryos and stem cells.

Authors:  Ariel Ruiz i Altaba; Pilar Sánchez; Nadia Dahmane
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

6.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis.

Authors:  Delphine Javelaud; Khalid S Mohammad; Christopher R McKenna; Pierrick Fournier; Flavie Luciani; Maryla Niewolna; Jocelyne André; Véronique Delmas; Lionel Larue; Theresa A Guise; Alain Mauviel
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

Review 7.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

Authors:  Keiran S M Smalley
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

Review 8.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.

Authors:  J J Yin; K Selander; J M Chirgwin; M Dallas; B G Grubbs; R Wieser; J Massagué; G R Mundy; T A Guise
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

Review 10.  Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development.

Authors:  Anne Vincent-Salomon; Jean Paul Thiery
Journal:  Breast Cancer Res       Date:  2003-02-03       Impact factor: 6.466

View more
  73 in total

1.  Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus.

Authors:  Ling Yang; Li-Shu Wang; Xiaoxin Luke Chen; Zoran Gatalica; Suimin Qiu; Zhihua Liu; Gary Stoner; Hongwei Zhang; Heidi Weiss; Jingwu Xie
Journal:  Int J Biochem Mol Biol       Date:  2012-02-10

Review 2.  Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells.

Authors:  Stephanie A Pangas
Journal:  Mol Cell Endocrinol       Date:  2011-07-07       Impact factor: 4.102

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

4.  Cell density sensing alters TGF-β signaling in a cell-type-specific manner, independent from Hippo pathway activation.

Authors:  Flore Nallet-Staub; Xueqian Yin; Cristèle Gilbert; Véronique Marsaud; Saber Ben Mimoun; Delphine Javelaud; Edward B Leof; Alain Mauviel
Journal:  Dev Cell       Date:  2015-03-09       Impact factor: 12.270

Review 5.  TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis.

Authors:  Delphine Javelaud; Vasileia I Alexaki; Sylviane Dennler; Khalid S Mohammad; Theresa A Guise; Alain Mauviel
Journal:  Cancer Res       Date:  2011-08-23       Impact factor: 12.701

Review 6.  Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Authors:  Nadia Rucci; Patrizia Sanità; Simona Delle Monache; Edoardo Alesse; Adriano Angelucci
Journal:  World J Clin Oncol       Date:  2014-08-10

7.  The role of TGF-β in bone metastasis: novel therapeutic perspectives.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Bonekey Rep       Date:  2012-06-06

8.  Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases.

Authors:  Fengshu Zhao; Xiangfeng He; Jianan Sun; Di Wu; Meng Pan; Miao Li; Songyan Wu; Rong Zhang; Chunguang Yan; Jun Dou
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

9.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

10.  Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.

Authors:  Fei Duan; Ming Lin; Chuanyin Li; Xia Ding; Guanxiang Qian; He Zhang; Shengfang Ge; Xianqun Fan; Jin Li
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.